Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension - PubMed
5 hours ago
- #pulmonary arterial hypertension
- #nanoparticle therapy
- #immunotherapy
- Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease with features like vascular remodeling and endothelial dysfunction.
- Existing targeted therapies have poor long-term outcomes, necessitating more effective treatments.
- Recent advances include integrating conventional medicine with nanoparticle-mediated drug delivery systems (nano-DDS) for improved bioavailability and targeting.
- Other key areas are TGF-beta/BMPR-II pathways, tyrosine kinase interventions, and immunotherapies targeting inflammation and immune imbalance.
- Emerging molecular targets include NOTCH3/HES-5 and E-selectin.
- Innovative approaches involve endothelial-like progenitor cell-based therapy and the ETRQβ-002 vaccine.
- Future advancements may come from combining conventional drugs, nanotechnology, and immunotherapy through multidisciplinary efforts.